Skip to main content
Top
Published in: Tumor Biology 2/2011

01-04-2011 | Research Article

Polymorphisms in the 5′- and 3′-untranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics

Authors: Cristiane Oliveira, Gustavo J. Lourenço, Priscilla M. R. Silva, Cassio Cardoso-Filho, Maira H. C. Favarelli, Neiva S. L. Gonçales, Maria S. C. Gurgel, Carmen S. P. Lima

Published in: Tumor Biology | Issue 2/2011

Login to get access

Abstract

The wild and the variant alleles of the C936T and G634C vascular endothelial grow factor (VEGF) polymorphisms seem to be linked to higher angiogenic phenotype than the remaining alleles and may act on breast cancer (BC) origin. We investigated the influence of the VEGF C936T and G634C polymorphisms on the occurrence and clinicopathologic characteristics of sporadic breast cancer (SBC) in 235 patients and 235 controls. Peripheral blood samples of all individuals were analysed by the polymerase chain reaction for identification of genotypes and by enzyme-linked immunosorbent assay (ELISA) for quantification of serum VEGF levels. The variant 634CC genotype isolated (16.2% versus 10.7%, P= 0.01) and in combination with the wild 936CC genotype (10.6% versus 5.5%, P= 0.01) were more common in patients than in controls. The carriers of the respective genotypes were under a 2.20-fold and a 3.08-fold increased risks for the disease. Additionally, the frequency of the wild 936CC genotype was higher in patients with tumours of histological grade III compared to those with tumours of I+II histological grades (84.0% versus 64.7%, P= 0.004) and in patients with positive oestrogen receptor tumours compared to those with tumours lacking oestrogen receptor expression (84.7% versus 73.9%, P= 0.02). Similar serum values of VEGF were seen in patients and controls with the distinct genotypes of the VEGF. The data suggest that the VEGF wild 936CC and the variant 634CC genotypes constitute inherited determinants of SBC and SBC aggressiveness in Brazil, but are not significant predictors of circulating VEGF levels.
Literature
1.
go back to reference El-Gohary YM, Metwally G, Saad RS, et al. Prognostic significance of intratumoral and peritumoral lymphatic density and blood vessel density in invasive breast carcinomas. Am J Clin Pathol. 2008;8(129):578–86.CrossRef El-Gohary YM, Metwally G, Saad RS, et al. Prognostic significance of intratumoral and peritumoral lymphatic density and blood vessel density in invasive breast carcinomas. Am J Clin Pathol. 2008;8(129):578–86.CrossRef
2.
go back to reference Berezov TT, Ovchinnikova LK, Kuznetsova OM, et al. Vascular endothelial growth factor in the serum of breast cancer patients. Bull Exp Biol Med. 2009;148:419–24.CrossRefPubMed Berezov TT, Ovchinnikova LK, Kuznetsova OM, et al. Vascular endothelial growth factor in the serum of breast cancer patients. Bull Exp Biol Med. 2009;148:419–24.CrossRefPubMed
3.
go back to reference Hu Z, Fan C, Livasy C, et al. A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med. 2009;16:7–9. Hu Z, Fan C, Livasy C, et al. A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med. 2009;16:7–9.
4.
go back to reference Mohammed RA, Ellis IO, Elsheikh S, et al. Lymphatic and angiogenic characteristics in breast cancer: morphometric analysis and prognostic implications. Breast Cancer Res Treat. 2009;113:261–73.CrossRefPubMed Mohammed RA, Ellis IO, Elsheikh S, et al. Lymphatic and angiogenic characteristics in breast cancer: morphometric analysis and prognostic implications. Breast Cancer Res Treat. 2009;113:261–73.CrossRefPubMed
5.
go back to reference Shivakumar S, Prabhakar BT, Jayashree K, et al. Evaluation of serum vascular endothelial growth factor (VEGF) and microvessel density (MVD) as prognostic indicators in carcinoma breast. J Cancer Res Clin Oncol. 2009;135:627–36.CrossRefPubMed Shivakumar S, Prabhakar BT, Jayashree K, et al. Evaluation of serum vascular endothelial growth factor (VEGF) and microvessel density (MVD) as prognostic indicators in carcinoma breast. J Cancer Res Clin Oncol. 2009;135:627–36.CrossRefPubMed
6.
go back to reference Carpini JD, Karam AK, Montgomery L. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis. 2010;13:43–58.CrossRefPubMed Carpini JD, Karam AK, Montgomery L. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis. 2010;13:43–58.CrossRefPubMed
7.
go back to reference Safali M, Karslioğlu Y, Arpaci F, et al. A distinct microvascular pattern accompanied by aggressive clinical course in breast carcinomas: a fact or a coincidence? Pathol Res Pract. 2010;206:93–7.CrossRefPubMed Safali M, Karslioğlu Y, Arpaci F, et al. A distinct microvascular pattern accompanied by aggressive clinical course in breast carcinomas: a fact or a coincidence? Pathol Res Pract. 2010;206:93–7.CrossRefPubMed
8.
go back to reference Renner W, Kotschan S, Hoffman C, et al. A common 936C/T mutation in the gene for vascular endothelial growth factor plasma levels. J Vasc Res. 2009;37:443–8.CrossRef Renner W, Kotschan S, Hoffman C, et al. A common 936C/T mutation in the gene for vascular endothelial growth factor plasma levels. J Vasc Res. 2009;37:443–8.CrossRef
9.
go back to reference Krippl P, Langsenlehner V, Renner W, et al. A common 936C/T gene polymorphism of vascular endothelial growth factor is associated with decrease breast cancer risk. Int J Cancer. 2003;106:469–71.CrossRef Krippl P, Langsenlehner V, Renner W, et al. A common 936C/T gene polymorphism of vascular endothelial growth factor is associated with decrease breast cancer risk. Int J Cancer. 2003;106:469–71.CrossRef
10.
go back to reference Jakubowska A, Gronwald J, Menkiszak J, et al. The VEGF_936_C>T 3′UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women. Cancer Lett. 2008;262:71–6.CrossRef Jakubowska A, Gronwald J, Menkiszak J, et al. The VEGF_936_C>T 3′UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women. Cancer Lett. 2008;262:71–6.CrossRef
11.
go back to reference Balasubramanian SP, Cox A, Cross SS, et al. Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity. Int J Cancer. 2007;121:1009–16.CrossRefPubMed Balasubramanian SP, Cox A, Cross SS, et al. Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity. Int J Cancer. 2007;121:1009–16.CrossRefPubMed
12.
go back to reference Langsenlehner U, Wolf G, Langsenlehner T, et al. Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian “tumor of breast tissue: incidence, genetics, and environmental risk factors” study. Breast Cancer Res Treat. 2008;109:297–304.CrossRefPubMed Langsenlehner U, Wolf G, Langsenlehner T, et al. Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian “tumor of breast tissue: incidence, genetics, and environmental risk factors” study. Breast Cancer Res Treat. 2008;109:297–304.CrossRefPubMed
13.
go back to reference Jin Q, Hemminki K, Enquist K, et al. Vascular endothelial growth factor polymorphism in relation to breast cancer development and prognosis. Clin Cancer Res. 2005;11:3647–53.CrossRefPubMed Jin Q, Hemminki K, Enquist K, et al. Vascular endothelial growth factor polymorphism in relation to breast cancer development and prognosis. Clin Cancer Res. 2005;11:3647–53.CrossRefPubMed
14.
go back to reference Jacobs EJ, Feigelson HS, Bain EB, et al. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res. 2006;8:R22–7.CrossRefPubMed Jacobs EJ, Feigelson HS, Bain EB, et al. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res. 2006;8:R22–7.CrossRefPubMed
15.
go back to reference Kataoka N, Cai Q, Wen W, et al. Population-based case-control study of VEGF gene polymorphism and breast cancer risk among Chinese women. Cancer Epidemiol Biomark Prev. 2006;15:1148–52.CrossRef Kataoka N, Cai Q, Wen W, et al. Population-based case-control study of VEGF gene polymorphism and breast cancer risk among Chinese women. Cancer Epidemiol Biomark Prev. 2006;15:1148–52.CrossRef
16.
go back to reference Schneider BP, Radovich M, Sledge GW, et al. Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat. 2008;111:157–63.CrossRefPubMed Schneider BP, Radovich M, Sledge GW, et al. Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat. 2008;111:157–63.CrossRefPubMed
17.
18.
go back to reference Xu B, Li JM, Tong N, et al. VEGFA +936C>T polymorphism and cancer risk: a meta-analysis. Cancer Genet Cytogenet. 2010;198:7–14.CrossRefPubMed Xu B, Li JM, Tong N, et al. VEGFA +936C>T polymorphism and cancer risk: a meta-analysis. Cancer Genet Cytogenet. 2010;198:7–14.CrossRefPubMed
19.
go back to reference Eroglu A, Oztürk A, Cam R, et al. Vascular endothelial growth factor gene 936C/T polymorphism in breast cancer patients. Med Oncol. 2005;25:54–5.CrossRef Eroglu A, Oztürk A, Cam R, et al. Vascular endothelial growth factor gene 936C/T polymorphism in breast cancer patients. Med Oncol. 2005;25:54–5.CrossRef
20.
go back to reference Lin GT, Tseng HF, Yang CH, et al. Combinational polymorphisms of seven CXCL12-related genes are protective against breast cancer in Taiwan. OMICS. 2009;13:165–72.CrossRefPubMed Lin GT, Tseng HF, Yang CH, et al. Combinational polymorphisms of seven CXCL12-related genes are protective against breast cancer in Taiwan. OMICS. 2009;13:165–72.CrossRefPubMed
21.
go back to reference Watson CJ, Webb NJ, Bottomley MJ, et al. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12:1232–5.CrossRefPubMed Watson CJ, Webb NJ, Bottomley MJ, et al. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12:1232–5.CrossRefPubMed
22.
go back to reference Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in the type 2 diabetes. Diabetes. 2002;51:1635–9.CrossRefPubMed Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in the type 2 diabetes. Diabetes. 2002;51:1635–9.CrossRefPubMed
24.
go back to reference Muniz JJ, Izidoro-Toledo TC, Metzger IF, et al. Interethnic differences in the distribution of clinically relevant vascular endothelial growth factor genetic polymorphisms. DNA Cell Biol. 2009;28:567–72.CrossRefPubMed Muniz JJ, Izidoro-Toledo TC, Metzger IF, et al. Interethnic differences in the distribution of clinically relevant vascular endothelial growth factor genetic polymorphisms. DNA Cell Biol. 2009;28:567–72.CrossRefPubMed
25.
go back to reference Alves-Silva J, Da Silva-Santos M, Guimarães, et al. The ancestry of Brazilian mtDNA lineages. Am J Hum Genet. 2009;67:444–61.CrossRef Alves-Silva J, Da Silva-Santos M, Guimarães, et al. The ancestry of Brazilian mtDNA lineages. Am J Hum Genet. 2009;67:444–61.CrossRef
26.
go back to reference Carvalho-Silva DR, Santos FR, Rocha J, et al. The phylogeography of Brazilian Y-chromosome lineages. Am J Hum Genet. 2001;68:281–6.CrossRefPubMed Carvalho-Silva DR, Santos FR, Rocha J, et al. The phylogeography of Brazilian Y-chromosome lineages. Am J Hum Genet. 2001;68:281–6.CrossRefPubMed
27.
go back to reference Yang DS, Park KH, Woo OH, Woo SU et al (2010) Association of a vascular endothelial growth factor gene 936C/T polymorphism with breast cancer risk: a meta-analysis. Breast Cancer Res Treat 21. doi:10.1007/s10549-010-1070-1 Yang DS, Park KH, Woo OH, Woo SU et al (2010) Association of a vascular endothelial growth factor gene 936C/T polymorphism with breast cancer risk: a meta-analysis. Breast Cancer Res Treat 21. doi:10.​1007/​s10549-010-1070-1
28.
go back to reference Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–10.CrossRefPubMed Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–10.CrossRefPubMed
29.
go back to reference Greene FL, Page DL, Fleming ID, et al. Breast. In: Balch CM, editor. AJCC Cancer staging manual. 6th ed. New York: Springer; 2002. p. 223–40. Greene FL, Page DL, Fleming ID, et al. Breast. In: Balch CM, editor. AJCC Cancer staging manual. 6th ed. New York: Springer; 2002. p. 223–40.
30.
go back to reference Papazoglou D, Galazios G, Koukourakis MI, et al. Vascular endothelial growth factor gene polymorphisms and pre-eclampsia. Mol Hum Reprod. 2000;10:321–4.CrossRef Papazoglou D, Galazios G, Koukourakis MI, et al. Vascular endothelial growth factor gene polymorphisms and pre-eclampsia. Mol Hum Reprod. 2000;10:321–4.CrossRef
31.
go back to reference Losordo DW, Isner JM. Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol. 2001;21:6–12.PubMed Losordo DW, Isner JM. Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol. 2001;21:6–12.PubMed
Metadata
Title
Polymorphisms in the 5′- and 3′-untranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics
Authors
Cristiane Oliveira
Gustavo J. Lourenço
Priscilla M. R. Silva
Cassio Cardoso-Filho
Maira H. C. Favarelli
Neiva S. L. Gonçales
Maria S. C. Gurgel
Carmen S. P. Lima
Publication date
01-04-2011
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2011
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-010-0121-x

Other articles of this Issue 2/2011

Tumor Biology 2/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine